SCHEMBL14825796

SCHEMBL14825796

CCOC(=O)c1ccc(CN2CCC(=C3c4ccccc4C=Cc4ccccc43)CC2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SETD7 Q8WTS6 3/20 0.52
▸ ALDH1A1 P00352 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ HRH1 P35367 2/20 0.43
▸ OPRM1 P35372 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ CHRM4 P08173 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ CHRM5 P08912 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ DRD2 P14416 1/20 0.43
▸ ADRA2B P18089 1/20 0.43
▸ ADRA2C P18825 1/20 0.43
▸ CHRM3 P20309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825804 0.89 KDM4E (0.52) SETD7ALDH1A1HRH1OPRM1TSHR
SCHEMBL14825797 0.85 SETD7 (0.52) SETD7ALDH1A1HSD17B10HRH1OPRM1
SCHEMBL9718763 0.77 SETD7 (0.63) SETD7ALDH1A1HSD17B10HRH1OPRM1
SCHEMBL8177110 0.76 HRH3 (0.55) ALDH1A1HSD17B10TSHRHTTLMNA
SCHEMBL14827209 0.75 SETD7 (0.49) SETD7ALDH1A1HSD17B10HRH1OPRM1
SCHEMBL8218752 0.75 SETD7 (0.59) SETD7ALDH1A1HSD17B10HRH1OPRM1
SCHEMBL9718808 0.75 SETD7 (0.60) SETD7ALDH1A1HSD17B10HRH1OPRM1
SCHEMBL12004328 0.75 FFAR1 (0.51) OPRM1LMNASMN1; SMN2OPRD1
Hydrochloric Acid SCHEMBL9718722 0.74 SETD7 (0.59) SETD7ALDH1A1HSD17B10HRH1OPRM1
SCHEMBL9718794 0.73 SETD7 (0.63) SETD7ALDH1A1HSD17B10HRH1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 SETD7 1711/4885ALDH1A1 2121/4885HSD17B10 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback